Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: TripleE3	7/17/2025 11:54:55 PM
	Read Replies (1) of 63281

SRPT 3rd Death from Liver Toxicity A month ago?! After yesterday's conference to calm the market? Now this. I guess this is the REAL REASON why they are laying off 500. Bunker mentality for when Elevidys gets pulled all together. "A third patient, a 51 year-old in a Phase I study of SRP-9004 for Limb-Girdle muscular dystrophy Type 2E, has died from a Sarepta gene therapy. Like two deaths associated with the company’s Duchenne muscular dystrophy gene therapy, Elevidys delandistrogene moxeparvovec, the most recent death was caused by acute liver toxicity, Sarepta Therapeutics Inc. (NASDAQ:SRPT) spokesperson Tracy Sorrentino told BioCentury."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next